Literature DB >> 15253947

Danon's disease as a cause of hypertrophic cardiomyopathy: a systematic survey.

P Charron1, E Villard, P Sébillon, P Laforêt, T Maisonobe, L Duboscq-Bidot, N Romero, V Drouin-Garraud, T Frébourg, P Richard, B Eymard, M Komajda.   

Abstract

BACKGROUND: Hypertrophic cardiomyopathy (HCM) is an autosomal dominant disease caused by mutations in sarcomeric genes. However, extensive genetic screening failed to identify a mutation in about a third of cases. One possible explanation is that other diseases, caused by other genes, may mimic HCM.
OBJECTIVE: To investigate the possible involvement of Danon's disease, an X linked lysosomal disease, in a large population of patients with HCM.
METHODS: A population of 197 index cases was considered; 124 were subsequently excluded because of a mutation in sarcomeric genes and 23 because of autosomal dominant inheritance. Fifty index cases were therefore included in molecular analysis (direct sequencing) of the lysosome associated membrane protein 2 (LAMP2) gene responsible for Danon's disease.
RESULTS: Two new mutations leading to premature stop codons were identified in patients who evolved towards severe heart failure (< 25 years old): 657C>T and 173_179del. The prevalence was therefore 1% of the total population (two of 197) or 4% of enrolled index cases (two of 50). Interestingly, Danon's disease was responsible for half of the cases (two of four) with HCM and clinical skeletal myopathy but was not involved in isolated HCM (none of 41).
CONCLUSIONS: Danon's disease may be involved in patients with previously diagnosed as HCM. A diagnosis strategy is proposed. To distinguish HCM from Danon's disease is important because the clinical evolution, prognosis, mode of inheritance, and therefore genetic counselling are very different.

Entities:  

Mesh:

Year:  2004        PMID: 15253947      PMCID: PMC1768382          DOI: 10.1136/hrt.2003.029504

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  13 in total

Review 1.  The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms.

Authors:  J G Seidman; C Seidman
Journal:  Cell       Date:  2001-02-23       Impact factor: 41.582

2.  Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy.

Authors:  Michael Arad; D Woodrow Benson; Antonio R Perez-Atayde; William J McKenna; Elizabeth A Sparks; Ronald J Kanter; Kate McGarry; J G Seidman; Christine E Seidman
Journal:  J Clin Invest       Date:  2002-02       Impact factor: 14.808

Review 3.  The molecular genetic basis for hypertrophic cardiomyopathy.

Authors:  A J Marian; R Roberts
Journal:  J Mol Cell Cardiol       Date:  2001-04       Impact factor: 5.000

Review 4.  Hypertrophic cardiomyopathy. Clinical spectrum and treatment.

Authors:  E D Wigle; H Rakowski; B P Kimball; W G Williams
Journal:  Circulation       Date:  1995-10-01       Impact factor: 29.690

Review 5.  Hypertrophic cardiomyopathy: a systematic review.

Authors:  Barry J Maron
Journal:  JAMA       Date:  2002-03-13       Impact factor: 56.272

6.  Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy.

Authors:  B Sachdev; T Takenaka; H Teraguchi; C Tei; P Lee; W J McKenna; P M Elliott
Journal:  Circulation       Date:  2002-03-26       Impact factor: 29.690

7.  Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy.

Authors:  Pascale Richard; Philippe Charron; Lucie Carrier; Céline Ledeuil; Theary Cheav; Claire Pichereau; Abdelaziz Benaiche; Richard Isnard; Olivier Dubourg; Marc Burban; Jean-Pierre Gueffet; Alain Millaire; Michel Desnos; Ketty Schwartz; Bernard Hainque; Michel Komajda
Journal:  Circulation       Date:  2003-04-21       Impact factor: 29.690

8.  Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease).

Authors:  I Nishino; J Fu; K Tanji; T Yamada; S Shimojo; T Koori; M Mora; J E Riggs; S J Oh; Y Koga; C M Sue; A Yamamoto; N Murakami; S Shanske; E Byrne; E Bonilla; I Nonaka; S DiMauro; M Hirano
Journal:  Nature       Date:  2000-08-24       Impact factor: 49.962

9.  Genetic testing and genetic counselling in hypertrophic cardiomyopathy: the French experience.

Authors:  P Charron; D Héron; M Gargiulo; P Richard; O Dubourg; M Desnos; J B Bouhour; J Feingold; L Carrier; B Hainque; K Schwartz; M Komajda
Journal:  J Med Genet       Date:  2002-10       Impact factor: 6.318

10.  Danon's disease (X-linked vacuolar cardiomyopathy and myopathy): a case with a novel Lamp-2 gene mutation.

Authors:  Laetitia Lacoste-Collin; Virginie Garcia; Emmanuelle Uro-Coste; Marie-Christine Arné-Bes; Dominique Durand; Thierry Levade; Marie-Bernadette Delisle
Journal:  Neuromuscul Disord       Date:  2002-11       Impact factor: 4.296

View more
  29 in total

1.  Danon disease. A novel mutation in the LAMP-2 gene and ophthalmic abnormality.

Authors:  J He; Y Wang; T Jiang
Journal:  Herz       Date:  2013-08-18       Impact factor: 1.443

Review 2.  Danon disease - dysregulation of autophagy in a multisystem disorder with cardiomyopathy.

Authors:  Teisha J Rowland; Mary E Sweet; Luisa Mestroni; Matthew R G Taylor
Journal:  J Cell Sci       Date:  2016-05-10       Impact factor: 5.285

3.  Time course analysis of gene expression identifies multiple genes with differential expression in patients with in-stent restenosis.

Authors:  Santhi K Ganesh; Jungnam Joo; Kimberly Skelding; Laxmi Mehta; Gang Zheng; Kathleen O'Neill; Eric M Billings; Anna Helgadottir; Karl Andersen; Gudmundur Thorgeirsson; Thorarinn Gudnason; Nancy L Geller; Robert D Simari; David R Holmes; William W O'Neill; Elizabeth G Nabel
Journal:  BMC Med Genomics       Date:  2011-02-28       Impact factor: 3.063

Review 4.  Insights and challenges in hypertrophic cardiomyopathy, 2012.

Authors:  Srijita Sen-Chowdhry; María Teresa Tomé Esteban; William J McKenna
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2012-09-25

5.  PLEKHM2 mutation leads to abnormal localization of lysosomes, impaired autophagy flux and associates with recessive dilated cardiomyopathy and left ventricular noncompaction.

Authors:  Emad Muhammad; Aviva Levitas; Sonia R Singh; Alex Braiman; Rivka Ofir; Sharon Etzion; Val C Sheffield; Yoram Etzion; Lucie Carrier; Ruti Parvari
Journal:  Hum Mol Genet       Date:  2015-10-12       Impact factor: 6.150

Review 6.  Hypertrophic cardiomyopathy: an updated review on diagnosis, prognosis, and treatment.

Authors:  George Makavos; Chris Κairis; Maria-Eirini Tselegkidi; Theodoros Karamitsos; Angelos G Rigopoulos; Michel Noutsias; Ignatios Ikonomidis
Journal:  Heart Fail Rev       Date:  2019-07       Impact factor: 4.214

Review 7.  Translating emerging molecular genetic insights into clinical practice in inherited cardiomyopathies.

Authors:  Babken Asatryan; Argelia Medeiros-Domingo
Journal:  J Mol Med (Berl)       Date:  2018-08-20       Impact factor: 4.599

8.  Danon disease presenting with dilated cardiomyopathy and a complex phenotype.

Authors:  Matthew R G Taylor; Lisa Ku; Dobromir Slavov; Jean Cavanaugh; Mark Boucek; Xiao Zhu; Sharon Graw; Elisa Carniel; Carl Barnes; Dianna Quan; Ryan Prall; Mark A Lovell; Gary Mierau; Patsy Ruegg; Naresh Mandava; Michael R Bristow; Jeffrey A Towbin; Luisa Mestroni
Journal:  J Hum Genet       Date:  2007       Impact factor: 3.172

9.  Mimics of Hypertrophic Cardiomyopathy - Diagnostic Clues to Aid Early Identification of Phenocopies.

Authors:  Rajiv Sankaranarayanan; Eleanor J Fleming; Clifford J Garratt
Journal:  Arrhythm Electrophysiol Rev       Date:  2013-04

Review 10.  Danon disease: clinical features, evaluation, and management.

Authors:  Ryan S D'souza; Cecilia Levandowski; Dobromir Slavov; Sharon L Graw; Larry A Allen; Eric Adler; Luisa Mestroni; Matthew R G Taylor
Journal:  Circ Heart Fail       Date:  2014-09       Impact factor: 8.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.